» Articles » PMID: 28583000

Suicide in Primary Headaches in 48 Countries: A Physician-survey Based Study

Overview
Journal Cephalalgia
Specialties Neurology
Psychiatry
Date 2017 Jun 7
PMID 28583000
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Aim To investigate the relationship between primary headache types and accomplished or attempted suicide in countries from all world regions. Methods Data were obtained using a questionnaire about suicide due to headache in a face-to-face interview with 203 physicians with expertise in headaches. They came from 48 countries, and from all continents. Results Primary headaches cause one suicide per 1,000,000 population each year (1% of the suicide rate due to all causes). Cluster headache and migraines account for 70-80% of them. Suicide attempts are 10 times more frequent than accomplished suicides. Cluster headache poses more risk than migraine. This risk is not often acknowledged, and is increased if there is previous psychiatric history. More than half of the physicians interviewed think it could be reduced with a more aggressive treatment of headaches. Conclusions Cluster headache and migraine are not always benign, and are the cause of the majority of suicides due to headache.

Citing Articles

Trigeminal Neuralgia: Disease Characterization and Prediction of Response to Surgical Intervention.

Lam J, Sankar T, Sekula R, Senatus P, Patil P Curr Pain Headache Rep. 2025; 29(1):37.

PMID: 39873810 DOI: 10.1007/s11916-024-01316-5.


Off-Label Cyproheptadine in Children and Adolescents: Psychiatric Comorbidities, Interacting Variables, Safety, and Risks of Hepatotoxicity.

Gupta M, Gupta N, Madabushi J Cureus. 2023; 15(1):e33745.

PMID: 36788882 PMC: 9922522. DOI: 10.7759/cureus.33745.


Regulatory Effects of Acupuncture on Emotional Disorders in Patients With Menstrual Migraine Without Aura: A Resting-State fMRI Study.

Zhang Y, Wang Z, Du J, Liu J, Xu T, Wang X Front Neurosci. 2021; 15:726505.

PMID: 34671239 PMC: 8521095. DOI: 10.3389/fnins.2021.726505.


Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study.

Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M J Headache Pain. 2021; 22(1):114.

PMID: 34600468 PMC: 8487575. DOI: 10.1186/s10194-021-01333-4.


Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache.

Kudrow D, Scott Andrews J, Rettiganti M, Oakes T, Bardos J, Gaul C Headache. 2020; 60(10):2254-2264.

PMID: 33179263 PMC: 7756634. DOI: 10.1111/head.14011.